Articles from China Medical System Holdings Limited
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Approved in Singapore, Filling Gap in Vitiligo Treatment
By China Medical System Holdings Limited · Via ACN Newswire · November 4, 2026
CMS: Initial Prescriptions for Silevimig Injection, the World's First Bispecific Antibody Against Rabies, Issued in China
By China Medical System Holdings Limited · Via ACN Newswire · September 9, 2026
CMS (867.HK/8A8.SG): Innovative Drug Lumirix(R) Approved in China for Additional Indication of Atopic Dermatitis (AD)
By China Medical System Holdings Limited · Via ACN Newswire · September 3, 2026
CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World's First Bispecific Antibody for Passive Immunization Against Rabies
By China Medical System Holdings Limited · Via ACN Newswire · June 22, 2026
CMS's (867.HK/8A8.SG) Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at the ADA Scientific Sessions
By China Medical System Holdings Limited · Via ACN Newswire · June 8, 2026
CMS (867.HK/8A8.SG) Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer(R) and Cosmofer(R)
By China Medical System Holdings Limited · Via ACN Newswire · April 27, 2026